Jul. 24 at 4:23 PM
$RDY Q1 earnings beat — but is the stock a buy?
EPS of 20 cents per ADS topped the Zacks Consensus Estimate of 18 cents.
Revenues grew 11% year over year to
$997 million, driven by growth in global generics revenues, surpassing estimates.
Yet, shares have slipped 7.5% year to date.
Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-body-3688&ADID=SYND_STOCKTWITS_TWEET_2_2613023_BODY_3688